Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule FULLERTON, Calif., September 29, 2026 – Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid pric
How this was made
The 30-second read
Why it matters
Regaining compliance removes a delisting threat, potentially reducing short‑interest pressure and allowing the stock to trade without the compliance cloud.
Market read
The filing is a primary disclosure of a compliance event that could modestly affect LIMN's price and set a precedent for similar small‑cap biotech listings.
What to watch
Future financing needs and clinical trial milestones remain critical for long‑term valuation.
Background
Liminatus Pharma (NASDAQ:LIMN) is a biotech developing immuno‑oncology and cell‑therapy candidates. The company previously fell below the $1.00 bid price threshold, prompting a Nasdaq notice and a reverse split.
Ticker impact
Liminatus Pharma announced it regained Nasdaq minimum bid price compliance after a 1-for-50 reverse split, removing a listing deficiency.
likely modest upside as market prices out the compliance news
The company was previously non‑compliant; regaining compliance eliminates a negative catalyst and may attract short covering.
Market effects
May improve sentiment for small‑cap biotech peers facing Nasdaq compliance issues.
Limited to U.S. Nasdaq market; no broader regional effect.
Minimal global impact.
Counterpoint
Price may stay flat if investors view compliance as a routine filing rather than a substantive improvement.
Key entities
- companyLiminatus Pharma, Inc.
Biotech issuer of ticker LIMN.
- regulatory_bodyNasdaq Hearings Panel
Granted the compliance extension and approved the transfer to the Capital Market.
